Cytokinetics, Incorporated filings document a specialty cardiovascular biopharmaceutical company with common stock listed on the Nasdaq Global Select Market. Its 8-K reports cover financial results, corporate presentations, MYQORZO® regulatory approvals, clinical and regulatory disclosures, and material capital-structure events such as underwriting agreements for common stock offerings.
Proxy materials describe board elections, executive compensation, auditor ratification and equity plan amendments, including matters tied to the company’s employee stock purchase plan. Other filings address governance changes, risk disclosures, registered securities, exhibits and Inline XBRL cover-page data associated with Cytokinetics’ public-company reporting obligations.
Cytokinetics (CYTK) reported an insider transaction by a director. On 10/15/2025, the director acquired 199 shares of common stock at $62.8 per share. Following the transaction, the director beneficially owns 20,692 shares, held directly.
The filing notes this was director equity in lieu of a cash retainer, indicating compensation received in stock rather than cash.
Cytokinetics (CYTK) reported an insider transaction by a director. On 10/15/2025, the director acquired 338 shares of common stock at $62.8 per share, noted as part of a director equity in lieu of cash retainer program.
Following the transaction, the director beneficially owned 74,578 shares direct and 83 shares indirect through a spouse.
Cytokinetics (CYTK) director Dr. Kaye reported an equity grant on 10/15/2025. The filing shows acquisition of 199 shares of common stock (Transaction Code A) at a reported price of $62.8, described as “director equity in lieu of cash retainer.” Following the transaction, Dr. Kaye beneficially owns 9,977 shares, held directly. This reflects routine director compensation paid in stock rather than cash.
Cytokinetics (CYTK) director reported acquiring common stock. On 10/15/2025, the director acquired 99 shares at $62.8 per share under the director equity in lieu of cash retainer program. After this transaction, the director beneficially owns 30,873 shares, held directly.
Insider exercise and sale by Cytokinetics EVP R&D. On 10/07/2025 Dr. Malik Fady Ibraham exercised a non‑qualified stock option to acquire $0.00 priced shares (2,000 shares) at an exercise price of $10.60 and simultaneously sold 2,000 shares at $60.56. Following these transactions his reported beneficial ownership is 140,610 shares.
CYTOKINETICS, Inc. director Dr. Edward M. Kaye reported a sale of 6,757 shares of common stock on 10/06/2025 under a transaction coded S (sale). The filing shows the sale price as $60 per share and that Dr. Kaye beneficially owned 9,778 shares following the transaction. The form is signed by an attorney-in-fact and the reporting box indicates the trade was made pursuant to a Rule 10b5-1 plan.
Insider sale notice for CytoKinetics (CYTK). An individual proposes to sell 6,757 common shares with an aggregate market value of $384,946.29, representing approximately 0.00565% of the 119,657,156 shares outstanding. The proposed approximate sale date is 10/06/2025 on NASDAQ. The shares were acquired as restricted stock units on 01/04/2021.
The filing also discloses recent automated sales under a 10b5-1 plan: 6,695 shares sold on 09/30/2025 for $368,727.79 and 6,756 shares sold on 09/02/2025 for $337,800.00. The filer certifies no undisclosed material adverse information and signals use of a trading plan or instructions consistent with Rule 10b5-1 practice.
Form 144 notice for CYTK reports a proposed sale of 15,000 common shares through Morgan Stanley Smith Barney on NASDAQ, with an aggregate market value of $824,400 and an approximate sale date of 10/01/2025. The shares were acquired as restricted stock units on 03/06/2021. The filing lists five prior 10b5-1 sales by the same person during Jul–Sep 2025 totalling 25,000 shares and gross proceeds shown for each trade. The filer certifies no undisclosed material adverse information and that the sale complies with Rule 144 and any applicable 10b5-1 plan.
Robert I. Blum, President & CEO and Director of Cytokinetics, reported a sale of common stock on 10/01/2025. The Form 4 shows 5,000 shares were disposed of at a price of $55.05. After the reported sale, the filing lists 368,108 shares held directly and 2,083 shares held indirectly by The Bridget Blum 2003 Irrevocable Trust and 2,083 shares held indirectly by The Brittany Blum 2003 Irrevocable Trust. The form was signed by an attorney-in-fact on behalf of Mr. Blum.
Insider sale disclosed: Dr. Edward M. Kaye, a director of Cytokinetics, Inc. (CYTK), reported a sale of 6,695 shares of the company's common stock on 09/30/2025 at a price of $55.08 per share. After this reported transaction, Dr. Kaye beneficially owned 16,535 shares, held directly. The Form 4 was signed by an attorney-in-fact, John Faurescu. The filing presents a single non-derivative sale and no derivative transactions were reported.